Fontolizumab

Fontolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	interferon gamma
Clinical data
ATC code	none;
Identifiers
CAS Number	326859-36-3 ;
ChemSpider	none;
UNII	6J92H2439Z;
KEGG	D04242 ;
Chemical and physical data
Molar mass	ca. 150 kg/mol
	(what is this?)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody^[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.^[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.^[3]

References[]

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
^ Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.
^ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.

[2] Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.

[3] Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov

[1]

[2]

[3]